The best students at the Regional BioCamp Alpe-Adria awarded
At the conclusion of the Regional BioCamp 2012, the winners of the competition part were announced. As a part of the event, which has been organized for the second time by Lek, a Sandoz Company, for promising science students from the Alpe-Adria region, Daliborka Dušanič from Biotechnical Faculty, Ljubljana and Miha Kosmač, a post-doctorial biomedicine researcher at the University of Ljubljana, developed the best case study. Selected was also the winning team with members Meti Gašparič Buh, Stefan Petrovski, Nejc Rački, Teja Rajar, Sara Seršen, Marko Viskić and Christine Winkler. The members of the winning team received a special acknowledgment for their work, while the individual winners will participate in the Novartis International BioCamp 2012 in Basel, Switzerland.
Regional BioCamp 2012 offered the participants insight into the pharmaceutical industry and entrepreneurship through expert lectures and visits to some of the development facilities at Sandoz Slovenia which are distinguished by high technology innovation and expertise. At the same time they had an opportunity to actively participate and challenge themselves in team work by developing case studies and in transferring already acquired knowledge into practical work.
The selection of the best team and two individuals was based on the participant’s collaboration in a team task. Olga Lipič, Head of Talent Development at Lek, a Sandoz company, a member of the panel for selecting the best case study on how to launch a biotechnological company in the competition part of the Regional BioCamp 2012, says: »Already at last year’s Regional BioCamp we had a chance to meet extremely talented students who proved themselves exceptionally well in culturally and professionally diverse teams. Excellent and productive collaboration was this year even more evident, as all competing groups prepared truly outstanding case studies which made our decision at the end even harder. In fact, they are all winners in that they proved themselves in every aspect of the BioCamp not only as science experts but also showing a considerable measure of business knowledge which was key in creating their business plans. I am sure that there is a highly successful career and an interesting life in front of them.«
According to the panel, the individual winners of the second Regional BioCamp, Daliborka Dušanič and Miha Kosmač, showed they were the best able to connect the scientific and business way of thinking, which is of key importance for success in the pharmaceutical industry. The winning team, which displayed a top performance and created the best business plan, described team work to be the key to their success. »Developing a business plan was truly very challenging as we are coming from the area of natural sciences and did not have this kind of experience with the business world before. The atmosphere in our team was very positive, all team members had an equal vote, we listened to the ideas of each other and took them into account when preparing the case study. Each of us had therefore an opportunity to express his/her opinion and creativity. We took our task very seriously and worked all night, and are, of course, very pleased with the result,« said Teja Rajar from the Ljubljana Biotechnical Faculty on behalf of the winning team.
»The impressions from the BioCamp are very positive. It was quite tough, as we worked hard on the case study, but it paid off in the end. All team members got on very well and the team work was truly excellent. I am delighted to receive this award and I am eagerly awaiting participating at the Novartis BioCamp,« said the individual winner Miha Kosmač.
The individual winner Daliborka Dušanič also thinks that team work was the key to her success at the BioCamp. »In particular I would like to highlight the excellent organization of the Regional BioCamp which provides a unique opportunity for students from different countries in our region to meet and network. I did not expect to win because all participants were very good at their work and produced their best. The work in our team was very coordinated, we managed to organize ourselves quickly and performed as a real team. This was definitely most important. For the moment my top priority is to gain my doctorate which I am defending in a month time. Winning at the Regional BioCamp is undoubtedly a valuable experience and a reference for work in this field also in the future,« she added.
The winners of the Regional BioCamp 2012 will join the participants at the annual Novartis International BioCamp, which will be held at the end of August this year in Basel, Switzerland. Together with the top young science experts from all around the globe they will attend a three-day seminar, gaining new knowledge and experience and learning about trends in biotechnology and biopharmacy.
The second Regional BioCamp in Ljubljana hosted 35 undergraduate and postgraduate students from eight countries: 19 participants from Slovenia, 16 from abroad, including four from Croatia, three each from Austria and Serbia, two from Macedonia and Italy and one student from Montenegro and Bosnia and Herzegovina.
Lek, a Sandoz company, is one of the pillars of leading world generics company Sandoz. Its role within Sandoz is to act as: a global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by valid and enforceable third-party patents. Sandoz has a portfolio of approximately 1000 compounds and sells its products in about 130 countries. Key product groups include cardiovascular medicines, anti-infectives, treatments for central nervous system and alimentary tract disorders, oncology and respiratory therapies, as well as medications for blood and blood forming organ disorders. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), and Oriel Therapeutics (US). In 2011, Sandoz employed more than 24,000 people (full-time equivalents) worldwide and achieved net sales of USD 9.5 billion for the full year. For more information, please visit www.sandoz.com.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/sandoz.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group’s continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 124,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32